Meconium ileus equivalent in a child with cystic fibrosis taking cimetidine

Area of Science:

• Pediatric Gastroenterology
• Pharmacology
• Cystic Fibrosis Research

Background:

• Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs, primarily the lungs and digestive system.
• Pancreatic insufficiency is common in CF, necessitating enzyme replacement therapy.
• Cimetidine, a histamine H2 receptor antagonist, has been explored for potential benefits in CF patients.

Observation:

• A pediatric patient with cystic fibrosis was administered cimetidine alongside standard pancreatic enzyme extract therapy.
• The addition of cimetidine appeared to decrease the frequency of bowel movements in the child.

Findings:

• Despite a reduction in stool frequency, the child developed meconium ileus equivalent.
• Meconium ileus equivalent is a serious complication characterized by inspissated meconium obstructing the bowel.
• The adverse event necessitated the discontinuation of cimetidine treatment.

Implications:

• This case highlights a potential risk of cimetidine in pediatric CF patients, specifically the development of meconium ileus equivalent.
• Clinicians should exercise caution when considering cimetidine for CF patients, monitoring closely for gastrointestinal complications.
• Further research may be needed to understand the interaction between cimetidine and CF pathophysiology or pancreatic enzyme therapy.